P3 Health Partners (PIII) Competitors

P3 Health Partners (NASDAQ:PIII) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Is PIII or XGN more profitable?

P3 Health Partners has a net margin of -9.99% compared to Exagen's net margin of -28.85%. Exagen's return on equity of -130.38% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-9.99%	-183.60%	-17.83%
Exagen	-28.85%	-130.38%	-34.69%

Does the media prefer PIII or XGN?

In the previous week, Exagen had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 8 mentions for Exagen and 6 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 1.23 beat Exagen's score of 0.97 indicating that P3 Health Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
P3 Health Partners	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer PIII or XGN?

P3 Health Partners presently has a consensus price target of $16.25, indicating a potential upside of 88.95%. Exagen has a consensus price target of $12.00, indicating a potential upside of 23.20%. Given P3 Health Partners' higher probable upside, research analysts clearly believe P3 Health Partners is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Exagen	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Do institutionals and insiders have more ownership in PIII or XGN?

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 17.8% of P3 Health Partners shares are held by company insiders. Comparatively, 12.6% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has higher valuation and earnings, PIII or XGN?

Exagen has lower revenue, but higher earnings than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.50B	0.04	-$135.85M	-$46.01	-0.19
Exagen	$55.64M	3.85	-$15.11M	-$0.89	-10.94

Which has more risk and volatility, PIII or XGN?

P3 Health Partners has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Summary

Exagen beats P3 Health Partners on 10 of the 17 factors compared between the two stocks.